An important role for VCAM-1, but not for ICAM-1 in restenosis following coronary stent implantation

Bayata, Serdar; Arıkan, Erdinç; Yeşìl, Murat; Postaci, Nursen; Taş, Abdülaziz; Köseoğlu, Mehmet

doi:10.5152/akd.2010.137

Cited by 16 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vascular cell adhesion molecule-1 (VCAM-1) is an immunoglobulin superfamily-specific receptor that provides high-affinity interactions between ECs and integrins on the leukocyte surface and facilitates transendothelial migration [10,13,14]. Moreover, VCAM-1 binds with monocytes, but not neutrophils, and it is the first CAM expressed in chronic inflammation such as atherosclerosis (before atherosclerotic plaque development) [13,14,24] and restenosis following coronary stent implantation [25]. Thus, VCAM-1 can be used as an indicator of in vitro EC activation during the early stages of inflammation.…”

Section: Introductionmentioning

confidence: 99%

Cytocompatibility and early inflammatory response of human endothelial cells in direct culture with Mg-Zn-Sr alloys

et al. 2017

View full text Add to dashboard Cite

Crystalline Mg-Zinc (Zn)-Strontium (Sr) ternary alloys consist of elements naturally present in the human body and provide attractive mechanical and biodegradable properties for a variety of biomedical applications. The first objective of this study was to investigate the degradation and cytocompatibility of four Mg-4Zn-xSr alloys (x = 0.15, 0.5, 1.0, 1.5 wt%; designated as ZSr41A, B, C, and D respectively) in the direct culture with human umbilical vein endothelial cells (HUVEC) in vitro. The second objective was to investigate, for the first time, the early-stage inflammatory response in cultured HUVECs as indicated by the induction of vascular cellular adhesion molecule-1 (VCAM-1). The results showed that the 24-h in vitro degradation of the ZSr41 alloys containing a β-phase with a Zn/Sr at% ratio ~1.5 was significantly faster than the ZSr41 alloys with Zn/Sr at% ~1. Additionally, the adhesion density of HUVECs in the direct culture but not in direct contact with the ZSr41 alloys for up to 24 h was not adversely affected by the degradation of the alloys. Importantly, neither culture media supplemented with up to 27.6 mM Mg2+ ions nor media intentionally adjusted up to alkaline pH 9 induced any detectable adverse effects on HUVEC responses. In contrast, the significantly higher, yet non-cytotoxic, Zn2+ ion concentration from the degradation of ZSr41D alloy was likely the cause for the initially higher VCAM-1 expression on cultured HUVECs. Lastly, analysis of the HUVEC-ZSr41 interface showed near-complete absence of cell adhesion directly on the sample surface, most likely caused by either a high local alkalinity, change in surface topography, and/or surface composition. The direct culture method used in this study was proposed as a valuable tool for studying the design aspects of Zn-containing Mg-based biomaterials in vitro, in order to engineer solutions to address current shortcomings of Mg alloys for vascular device applications.

show abstract

Section: Introductionmentioning

confidence: 99%

Cytocompatibility and early inflammatory response of human endothelial cells in direct culture with Mg-Zn-Sr alloys

et al. 2017

View full text Add to dashboard Cite

show abstract

“… 24 In addition to atherosclerotic plaque formation, adhesion molecules might also be involved in the generation of restenotic neointima. 25 VCAM-1 was overtly upregulated in neointimal smooth muscle cells in an animal model of wire-induced vascular injury. 26 In genetically hypercholesterolemic mice, VCAM-1 antibodies protect from neointima generation.…”

Section: Discussionmentioning

confidence: 92%

Resveratrol prevents TNF-α-induced VCAM-1 and ICAM-1 upregulation in endothelial progenitor cells via reduction of NF-κB activation

et al. 2020

View full text Add to dashboard Cite

Objective To assess the effects of resveratrol (RSV) on expression of adhesion molecules in endothelial progenitor cells (EPCs) following tumor necrosis factor-α (TNF-α) stimulation. Methods EPCs were treated with RSV and stimulated with TNF-α. A mononuclear cell (MNC) adhesion assay was used to assess the effects of RSV on TNF-α-induced MNC adhesion. Vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and E-selectin expression levels and nuclear factor κB (NF-κB) activation were assessed by immunoblotting. Results MNC adhesion to TNF-α-treated EPCs and VCAM-1/ICAM-1/E-selectin levels in EPCs were increased following TNF-α stimulation and decreased following RSV treatment. TNF-α enhanced NF-κB inhibitor α (IκB-α) phosphorylation in the cytosol as well as nuclear NF-κB p65 levels, both of which were decreased by RSV. Conclusions These findings provide new insights into RSV’s anti-inflammatory and anti-atherosclerotic effects. RSV’s mechanism of action might involve downregulation of VCAM-1, ICAM-1 and E-selectin by partial blockade of TNF-α-induced NF-κB activation and IκB-α phosphorylation in EPCs.

show abstract

“…Inflammation is not only central to the pathogenesis of atherosclerosis and plaque instability, but also contributes to adverse clinical outcomes related to PCI . A growing body of clinical research has demonstrated that circulating inflammatory markers (VCAM‐1, ICAM‐1, MCP‐1, IL‐6 and CRP) are strong predictors for mortality and future cardiovascular events in many clinical settings, including ACS patients following PCI . Previous studies have reported that berberine can inhibit the expression of tumour necrosis factor‐α, MCP‐1, IL‐6 and cyclo‐oxygenase‐2 in stimulated macrophages by activating AMP kinase or inhibiting extracellular signal‐regulating kinase (ERK) 1/2 .…”

Section: Discussionmentioning

confidence: 99%

“…[5][6][7]21 A growing body of clinical research has demonstrated that circulating inflammatory markers (VCAM-1, ICAM-1, MCP-1, IL-6 and CRP) are strong predictors for mortality and future cardiovascular events in many clinical settings, including ACS patients following PCI. [22][23][24][25][26] Previous studies have reported that berberine can inhibit the expression of tumour necrosis factor-a, MCP-1, IL-6 and cyclo-oxygenase-2 in stimulated macrophages by activating AMP kinase or inhibiting extracellular signal-regulating kinase (ERK) 1/2. 16,17,19 In the present study, we found that berberine treatment for 30 days decreased circulating levels of several inflammatory markers, namely VCAM-1, ICAM-1 and MMP-9, in ACS patients after PCI.…”

Section: Discussionmentioning

confidence: 99%

Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention

Shao

Wang²,

Huang

et al. 2012

Clin Exp Pharma Physio

View full text Add to dashboard Cite

1. Inflammation is central to the pathogenesis of acute coronary syndrome (ACS) and is associated with adverse clinical outcomes after percutaneous coronary intervention (PCI). Recent in vitro work has demonstrated the anti-inflammatory effect of berberine, a primary component of the traditional Chinese medicine 'umbellatine'. In the present study, we further tested whether berberine had any beneficial effects on ACS patients following PCI. 2.In all, 130 ACS patients undergoing PCI were recruited to the present study. Sixty-one patients were treated with berberine (300 mg, t.i.d., for 30 days) in addition to standard therapy, whereas the remaining patients received standard therapy alone. Circulating inflammatory markers were measured by ELISA, whereas serum lipid profiles were measured by routine chemical assays. 3.In the berberine-treated group, matrix metalloproteinase (MMP)-9, intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, C-reactive protein, interleukin-6 and monocyte chemoattractant protein-1 were significantly reduced relative to baseline values. Furthermore, the changes in MMP-9, ICAM-1 and VCAM-1 from baseline to after 1 month of treatment differed significantly between the two patient groups. There was a tendency for berberine to induce a slightly greater reduction in low-density lipoprotein cholesterol and triglycerides than standard therapy alone, without affecting high-density lipoprotein cholesterol, but the differences failed to reach statistical significance. No severe adverse effects of berberine were observed. 4.The results of the present study provide the first clinical evidence of the anti-inflammatory action of berberine in ACS patients following PCI. Berberine may become adjunct therapy to further improve clinical outcomes via its anti-inflammatory effect in ACS patients.

show abstract

An important role for VCAM-1, but not for ICAM-1 in restenosis following coronary stent implantation

Cited by 16 publications

References 27 publications

Cytocompatibility and early inflammatory response of human endothelial cells in direct culture with Mg-Zn-Sr alloys

Cytocompatibility and early inflammatory response of human endothelial cells in direct culture with Mg-Zn-Sr alloys

Resveratrol prevents TNF-α-induced VCAM-1 and ICAM-1 upregulation in endothelial progenitor cells via reduction of NF-κB activation

Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention

Contact Info

Product

Resources

About